- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01068145
Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)
March 25, 2015 updated by: Merck Sharp & Dohme LLC
Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled, Incomplete Crossover, Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and COPD Patients
Trial to evaluate the dose response of SCH 527123 in reducing inflammation from an ozone-induced sputum neutrophilia in both healthy subjects and subjects with COPD.
Study Overview
Status
Terminated
Conditions
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Part 1
- Subject of either sex and of any race between the age of 18 and 55 years, with a BMI (weight [kg]/height [m2]) between 19 and 32.
- Subject must have a FEV1 ≥ 80 % of predicted value.
- Subject must be nonsmoker (including cigarettes, cigars and pipes) or exsmoker who has stopped smoking for at least 6 months (smoking history ≤ 5 pack years).
- Subject's clinical laboratory tests (CBC, blood chemistry, urinalysis) must be within normal limits. Subjects must have a neutrophil count of >2.0 x 109/L. (also Part 2)
- Subject must be free of any clinically significant disease that would interfere with the study evaluations (also Part 2).
- Screening ECG conduction intervals must be within gender specific normal range; QTcB males ≤430 msec and females ≤450 msec (also Part 2).
- Vital sign measurements must be: a) oral body temperature, between 35.0°C and 37.5°C; b) systolic blood pressure, 90 to 140 mm Hg (160 mm Hg, Part 2); c) diastolic blood pressure, 45 to 90 mm Hg (100 mm Hg, Part 2); d) pulse rate, 40 to 100 bpm.
- Subject and partner(s) must be using an accepted method of contraception during the trial through 2 months post-treatment (also Part 2).
- Prior to randomization, subject must be a responder to ozone (also Part 2).
Part 2
- Subject with a diagnosis of COPD for at least 1 year and FEV1 ≥65% of predicted value post bronchodilation (measurement 30 minutes after 400 mcg salbutamol administration) and FEV1/FVC of <70%.
- Subject of either sex and of any race between the age of 40 and 65 years, with a BMI between 19 and 32.
- Subject must be active or exsmoker (cigarettes, cigars and/or pipes).
- Subject must have a normal exercise stress test (no clinically significant ECG findings).
Exclusion Criteria:
Part 1 and Part 2
- Female subject who is pregnant, intends to become pregnant (within 3 months of ending the study), or is breastfeeding.
- Subject with history of seasonal or perennial allergic rhinitis (ie, season for specific allergen).
- Subject who has an allergy or a contraindication to excipients in placebo or SCH 527123 formulations or salbutamol.
- Surgical or medical condition (history or presence) which might alter the ADME of the drug: a) inflammatory bowel disease, ulcers, gastrointestinal or rectal bleeding; b) major gastrointestinal tract surgery, ie, gastrectomy, gastroenterostomy, or bowel resection; c) pancreatic injury or pancreatitis; d) liver disease or injury; e) impaired renal function indicated by abnormal creatinine, urinary albumin, BUN/urea or clinical significant urinary cellular constituents (eg, cast); or f) urinary obstruction or difficulty in voiding.
- Subject who has any infectious disease within 4 weeks prior to drug administration.
- Subject who is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV.
- Subject who has a positive screen for drugs with a high potential for abuse (Screening and/or treatment period).
- Subjects with a history of mental instability or who have been treated for mood disorder.
- Subject with a history of alcohol or drug abuse in the past 2 years.
- Subject who has donated blood in the past 60 days.
- Subject who has demonstrated allergic reactions (eg, food, drug, atopic reactions or asthmatic episodes) which may interfere with ability to participate in the trial.
- Subject who has previously received SCH 527123 (Part 2 only)
Subject who has received any of the following treatments more recently than indicated washout period prior to Baseline:
- Parts 1 and 2: OTC medications (excluding paracetamol), 14 days.
- Part 1: prescription medications, 14 days; investigational drugs, 30 days.
- Part 2: vitamins and herbal supplements, 14 days; statins, 4 weeks; steroids (inhaled), 4 weeks; steroids (oral and dermal), 8 weeks; antibiotics, 6 weeks; leukotriene antagonists, 4 weeks; NSAIDS, 2 weeks.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Very low dose SCH 527123
|
Very low dose SCH 527123, once daily for 7 days
Low dose SCH 527123, once daily for 7 days
Medium dose SCH 527123, once daily for 7 days
High dose SCH 527123, once daily for 7 days
Low dose capsule SCH 527123, once daily for 14 days
Medium dose capsule SCH 527123, once daily for 14 days
High dose capsule SCH 527123, once daily for 14 days
|
Experimental: Low dose SCH 527123
|
Very low dose SCH 527123, once daily for 7 days
Low dose SCH 527123, once daily for 7 days
Medium dose SCH 527123, once daily for 7 days
High dose SCH 527123, once daily for 7 days
Low dose capsule SCH 527123, once daily for 14 days
Medium dose capsule SCH 527123, once daily for 14 days
High dose capsule SCH 527123, once daily for 14 days
|
Experimental: Medium dose SCH 527123
|
Very low dose SCH 527123, once daily for 7 days
Low dose SCH 527123, once daily for 7 days
Medium dose SCH 527123, once daily for 7 days
High dose SCH 527123, once daily for 7 days
Low dose capsule SCH 527123, once daily for 14 days
Medium dose capsule SCH 527123, once daily for 14 days
High dose capsule SCH 527123, once daily for 14 days
|
Experimental: High dose SCH 527123
|
Very low dose SCH 527123, once daily for 7 days
Low dose SCH 527123, once daily for 7 days
Medium dose SCH 527123, once daily for 7 days
High dose SCH 527123, once daily for 7 days
Low dose capsule SCH 527123, once daily for 14 days
Medium dose capsule SCH 527123, once daily for 14 days
High dose capsule SCH 527123, once daily for 14 days
|
Placebo Comparator: Placebo to match SCH 527123
|
Placebo capsules to match SCH 527123, once daily for 7 days
Placebo capsules to match SCH 527123, once daily for 14 days
|
Experimental: Low dose SCH 527123 (Part 2)
|
Very low dose SCH 527123, once daily for 7 days
Low dose SCH 527123, once daily for 7 days
Medium dose SCH 527123, once daily for 7 days
High dose SCH 527123, once daily for 7 days
Low dose capsule SCH 527123, once daily for 14 days
Medium dose capsule SCH 527123, once daily for 14 days
High dose capsule SCH 527123, once daily for 14 days
|
Experimental: Medium dose SCH 527123 (Part 2)
|
Very low dose SCH 527123, once daily for 7 days
Low dose SCH 527123, once daily for 7 days
Medium dose SCH 527123, once daily for 7 days
High dose SCH 527123, once daily for 7 days
Low dose capsule SCH 527123, once daily for 14 days
Medium dose capsule SCH 527123, once daily for 14 days
High dose capsule SCH 527123, once daily for 14 days
|
Experimental: High dose SCH 527123 (Part 2)
|
Very low dose SCH 527123, once daily for 7 days
Low dose SCH 527123, once daily for 7 days
Medium dose SCH 527123, once daily for 7 days
High dose SCH 527123, once daily for 7 days
Low dose capsule SCH 527123, once daily for 14 days
Medium dose capsule SCH 527123, once daily for 14 days
High dose capsule SCH 527123, once daily for 14 days
|
Placebo Comparator: Placebo (Part 2)
|
Placebo capsules to match SCH 527123, once daily for 7 days
Placebo capsules to match SCH 527123, once daily for 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PD/PK: Dose response of SCH 527123 on ozone-induced sputum neutrophilia in healthy subjects (Part 1) and subjects with COPD (Part 2), measured by placebo-adjusted percent change in sputum neutrophil counts and absolute sputum neutrophil counts.
Time Frame: Part 1, four treatment periods, Part 2 three treatment periods duration of the trial.
|
Part 1, four treatment periods, Part 2 three treatment periods duration of the trial.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
March 1, 2011
Study Registration Dates
First Submitted
February 11, 2010
First Submitted That Met QC Criteria
February 11, 2010
First Posted (Estimate)
February 12, 2010
Study Record Updates
Last Update Posted (Estimate)
March 26, 2015
Last Update Submitted That Met QC Criteria
March 25, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P05567
- 2008-006650-18 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on SCH 527123
-
Merck Sharp & Dohme LLCWithdrawn
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedNon-small Cell Lung Cancer | Solid Tumors | Castration Resistant Prostate Cancer | Microsatellite Stable Colorectal CancerCanada, United States, Australia, Israel, Korea, Republic of
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedPrimary Hypercholesterolemia | Mixed Hyperlipidemia
-
ALK-Abelló A/SCompleted
-
National Cancer Institute (NCI)Active, not recruitingStage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Lentigo Maligna Melanoma | Mucosal Melanoma | Acral Lentiginous Melanoma | Cutaneous Nodular Melanoma | Low-CSD MelanomaUnited States
-
Merck Sharp & Dohme LLCCompletedLymphoma, Non-Hodgkin | Multiple Myeloma | Solid Tumors | Leukemia, Lymphocytic, Chronic. B-Cell
-
ALK-Abelló A/SCompletedConjunctivitis | Rhinitis Allergic
-
M.D. Anderson Cancer CenterSchering-PloughWithdrawnGlioblastoma